Brief: Trilink Biotechnologies Expands Its mRNA Raw Material Offering
Sept 13 (Reuters) - Maravai LifeSciences Holdings Inc
MRVI.O :
* TRILINK BIOTECHNOLOGIES, PART OF MARAVAI LIFESCIENCES,
EXPANDS
ITS MRNA RAW MATERIAL OFFERING WITH THE FIRST GMP-GRADE MODIFIED
NUCLEOSIDE-TRIPHOSPHATE PRODUCT
Source text for Eikon: ID:nGNX1nP5FB
Further company coverage: MRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maravai Lifesciences Holdings
See all newsMaravai LifeSciences Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Maravai LifeSciences Q2 revenue beats estimates on strong TriLink demand
Maravai LifeSciences Holdings Inc expected to post a loss of 4 cents a share - Earnings Preview
Maravai LifeSciences Q1 revenue rises on higher CleanCap sales
Brief: Maravai LifeSciences Q1 Revenue USD 65.8 Million Vs. IBES Estimate USD 53 Million